PLUS-IS-LESS项目:基于降钙素原与肺部超声指导瑞士急诊科下呼吸道感染患者抗生素治疗:实用性阶梯楔形整群随机试验研究方案
该研究为在瑞士10个急诊科开展的实用性阶梯楔形整群随机试验,评估联合临床预测评分、肺部超声、降钙素原和临床严重度评分的PLUS算法指导成人下呼吸道感染抗生素使用,并与常规诊疗比较;共同主要终点为第28天抗生素处方比例和临床失败比例。
要点
- PLUS算法联合临床评分、肺部超声、降钙素原和严重度评分指导抗生素使用。
- 研究在瑞士10个急诊科开展,采用阶梯楔形整群随机设计。
- 共同主要终点为第28天抗生素处方比例与临床失败比例。
核心结论
- PLUS算法旨在通过提高诊断性能和最大化医生依从性来优化抗生素处方,同时确保安全性。
- 若结果成功,预期减少的抗生素处方比例可能不仅减少副作用和成本,还可能减轻抗生素耐药。
研究设计与样本
- PLUS-IS-LESS研究是一项在瑞士10个急诊科开展的实用性阶梯楔形整群随机临床试验。
- 研究评估PLUS算法与常规诊疗相比,在成人下呼吸道感染患者中指导抗生素使用。
- PLUS算法结合临床预测评分、肺部超声、降钙素原和临床严重度评分。
主要发现
- 共同主要终点为第28天处方抗生素的患者比例和第28天临床失败的患者比例。
- 次要终点包括生活质量变化、住院时长、抗生素相关副作用、实施障碍与促进因素、干预的成本效益以及使用机器学习识别肺部超声肺炎模式。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lower respiratory tract infections (LRTIs) are among the most frequent infections and a significant contributor to inappropriate antibiotic prescription. Currently, no single diagnostic tool can reliably identify bacterial pneumonia. We thus evaluate a multimodal approach based on a clinical score, lung ultrasound (LUS), and the inflammatory biomarker, procalcitonin (PCT) to guide prescription of antibiotics. LUS outperforms chest X-ray in the identification of pneumonia, while PCT is known to be elevated in bacterial and/or severe infections. We propose a trial to test their synergistic potential in reducing antibiotic prescription while preserving patient safety in emergency departments (ED). METHODS: The PLUS-IS-LESS study is a pragmatic, stepped-wedge cluster-randomized, clinical trial conducted in 10 Swiss EDs. It assesses the PLUS algorithm, which combines a clinical prediction score, LUS, PCT, and a clinical severity score to guide antibiotics among adults with LRTIs, compared with usual care. The co-primary endpoints are the proportion of patients prescribed antibiotics and the proportion of patients with clinical failure by day 28. Secondary endpoints include measurement of change in quality of life, length of hospital stay, antibiotic-related side effects, barriers and facilitators to the implementation of the algorithm, cost-effectiveness of the intervention, and identification of patterns of pneumonia in LUS using machine learning. DISCUSSION: The PLUS algorithm aims to optimize prescription of antibiotics through improved diagnostic performance and maximization of physician adherence, while ensuring safety. It is based on previously validated tests and does therefore not expose participants to unforeseeable risks. Cluster randomization prevents cross-contamination between study groups, as physicians are not exposed to the intervention during or before the control period. The stepped-wedge implementation of the intervention allows effect calculation from both between- and within-cluster comparisons, which enhances statistical power and allows smaller sample size than a parallel cluster design. Moreover, it enables the training of all centers for the intervention, simplifying implementation if the results prove successful. The PLUS algorithm has the potential to improve the identification of LRTIs that would benefit from antibiotics. When scaled, the expected reduction in the proportion of antibiotics prescribed has the potential to not only decrease side effects and costs but also mitigate antibiotic resistance. TRIAL REGISTRATION: This study was registered on July 19, 2022, on the ClinicalTrials.gov registry using reference number: NCT05463406. TRIAL STATUS: Recruitment started on December 5, 2022, and will be completed on November 3, 2024. Current protocol version is version 3.0, dated April 3, 2023.
引用
- Bessat C, Bingisser R, Schwendinger M, et al. PLUS-IS-LESS project: Procalcitonin and Lung UltraSonography-based antibiotherapy in patients with Lower rESpiratory tract infection in Swiss Emergency Departments: study protocol for a pragmatic stepped-wedge cluster-randomized trial. Trials. 2024. PMID: 38273319. doi:10.1186/s13063-023-07795-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。